Atugen Biotechnology GmbH, Roche Bioscience deal

Atugen will use its GeneBloc technology, which reduces expression of target genes, to validate Roche’s gene targets in inflammatory diseases. Atugen will assay the level of attenuation of the gene targets and examine the result of gene knock down in systems of interest, and will transfer resulting technology to Roche for its internal use. ...